Longeveron Announces CEO Transition
May 09 2022 - 4:15PM
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or
"Company") announced today the resignation of Chief Executive
Officer (CEO) Geoff Green, who is leaving the Company effective
June 1st, 2022, to pursue new opportunities. Longeveron’s Board of
Directors has approved the appointment of current Chief Medical
Officer, K. Chris Min, M.D., Ph.D., as Interim CEO, to succeed Mr.
Green. The Board has formed a search committee and retained an
executive search firm to assist in identifying a permanent CEO. The
Company currently intends to enter into a consulting agreement with
Mr. Green to further ensure a smooth transition.
“On behalf of the entire Board of Directors, I
want to extend our sincere appreciation to Geoff for his service
and contributions to Longeveron over the past 6 years,” said Joshua
M. Hare, M.D., Chairman of the Board of Directors and Chief Science
Officer. “Under his leadership, we have made significant strides,
advancing Lomecel-B into clinical trials for multiple indications,
and transitioning from a privately held pre-clinical enterprise to
a leading public company in the cell therapy field. We wish him all
the best in his future endeavors.”
Dr. Min has extensive pharma and biotech
clinical development experience, including work developing novel
cell therapies, leading research and development (R&D) and
clinical teams, and advancing regulatory engagements with the U.S.
Food and Drug Administration (FDA) from early clinical stage
Investigational New Drug (IND) applications through to pre-approval
New Drug Applications (NDA). Prior to joining Longeveron, Dr. Min
served as Vice President and Head of Medical & Clinical
Development at Enterin Inc.
“As Chief Medical Officer Dr. Min has already
brought tremendous value to Longeveron. We are confident this will
be a smooth transition as we work to identify the next leader for
the Company and continue to execute on our mission of delivering
living cell therapies to patients with chronic aging-related
diseases and other specific life-threatening conditions,” said Dr.
Hare.
About LongeveronLongeveron is a
clinical stage biotechnology company developing cellular therapies
for specific aging-related and life-threatening conditions. The
Company’s lead investigational product is the LOMECEL-B™ cell-based
therapy product (“Lomecel-B”), which is derived from
culture-expanded medicinal signaling cells (MSCs) that are sourced
from bone marrow of young, healthy adult donors. Longeveron
believes that by using the same cells that promote tissue repair,
organ maintenance, and immune system function, it can develop safe
and effective therapies for some of the most difficult disorders
associated with the aging process and other medical disorders.
Longeveron is currently sponsoring Phase 1 and 2 clinical trials in
the following indications: Aging Frailty, Alzheimer’s disease, the
Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS), and
hypoplastic left heart syndrome (HLHS). The Company’s mission is to
advance Lomecel-B into pivotal Phase 3 trials, with the goal of
achieving regulatory approvals, subsequent commercialization, and
broad use by the healthcare community. Additional information about
the Company is available at www.longeveron.com.
INVESTORS & MEDIA:
Investors:Elsie YauStern
Investor RelationsTel: (212) 698-8700 Email:
elsie.yau@sternir.com
Media:Neil HareGVC Strategies
Tel: (202) 550-0297Email: neil@gvcstrategies.com
Longeveron (NASDAQ:LGVN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Longeveron (NASDAQ:LGVN)
Historical Stock Chart
From Sep 2023 to Sep 2024